Morgan Stanley analyst Judah Frommer assumed coverage of Blueprint Medicines (BPMC) with an Equal Weight rating and price target of $100, down from $120. The firm sees Ayvakit ramping to a $2B commercial franchise within the next five years, but awaits incremental updates for next-generation Ellenstein to further underwrite the franchise peak sales guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Balanced Outlook on Blueprint Medicines: Growth Prospects and Market Dynamics
- Blueprint Medicines assumed with an Equal Weight at Morgan Stanley
- Coinbase initiated, Block upgraded: Wall Street’s top analyst calls
- Wolfe Research starts Blueprint Medicines at Outperform on bullish Ayvakit view
- Blueprint Medicines initiated with an Outperform at Wolfe Research